Shares of Lupin are in focus on Monday morning after the pharma major said its wholly owned subsidiary, Nanomi BV, has signed a definitive agreement to acquire VISUfarma BV, a European specialty pharmaceutical company backed by GHO Capital Partners for an enterprise value of 190 million euros or roughly Rs 1,970 crore. The acquisition will be funded through existing cash on balance sheet. VISUfarma 2025 estimated revenue stood at 54 million euros. Advertisement

VISUfarma has a portfolio of more than 60 branded ophthalmology products and established operations across Italy, the UK, Spain, Germany and France. The deal will give Lupin direct presence in major European markets and expand its specialty franchise in ophthalmology.

Lupin shares are down 6 per cent in the past one month and 19

See Full Page